Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: A preliminary report

E. E. Vokes, R. Rosenberg, M. Jahanzeb, J. Craig, R. Gralla, C. Belani, S. Jones, J. Bigley, J. Hohneker, Gralla, O'Rourke, Crawford, Tuttle, Viallet, Moinpour

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France) is a novel semisynthetic vinca alkaloid with antitumor activity in non-small cell lung cancer. An oral preparation of this drug is under investigation and was tested in a multicenter phase II study in patients with stage IV measurable or evaluable non-small cell lung cancer. The initial vinorelbine dose was 100 mg/m2/wk (80 mg/m2/wk for patients with prior radiotherapy). Following an initial 37% incidence of grade 3 or 4 neutropenia, the dose was reduced by 40 mg/dose. Nausea, vomiting, diarrhea, and mucositis were other frequently observed toxicities. A preliminary analysis indicated a response rate of 14%, suggesting activity of this drug when administered orally.

Original languageEnglish (US)
Pages (from-to)35-41
Number of pages7
JournalSeminars in Oncology
Volume21
Issue number5 SUPPL. 10
StatePublished - Jan 1 1994
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Vokes, E. E., Rosenberg, R., Jahanzeb, M., Craig, J., Gralla, R., Belani, C., Jones, S., Bigley, J., Hohneker, J., Gralla, O'Rourke, Crawford, Tuttle, Viallet, & Moinpour (1994). Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: A preliminary report. Seminars in Oncology, 21(5 SUPPL. 10), 35-41.